Sign up USA
Proactive Investors - Run By Investors For Investors

Motif Bio completes FDA submission for Iclaprim antibiotic

The AIM-listed bio-pharma company said Iclaprim had received Qualified Infectious Disease Product designation from the FDA together with Fast Track Designation
If accepted by the FDA, Iclaprim will have a review period of six months rather than ten

Motif Bio Plc (LON:MTFB) has completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its new antibiotic Iclaprim.

The AIM-listed bio-pharma company said Iclaprim, a targeted, Gram-positive investigational antibiotic for the treatment of acute bacterial skin and skin structure infections, had received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track Designation.

WATCH: Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim

The group added that upon acceptance of the filing of the NDA by the FDA, Iclaprim would receive priority review, a review period of six months instead of the standard ten months. 

If Iclaprim is approved as a new chemical entity with QIDP designation, it will be eligible for 10 years of market exclusivity in the US starting from the date of approval.

The news follows an announcement earlier this week when Motif confirmed that Iclaprim was confirmed to be better tolerated and safer than a rival drug in two recent late-stage studies.

In early-morning trading Thursday, Motif Bio shares were up 1% at 32.7p.

--Adds share price--

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use